Pharmaceutical Rsrch & Mfrs of America
Pharmaceutical Research and Manufacturers of America (PhRMA), founded in 1958, is a trade group representing the pharmaceutical research and biotechnology companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies. PhRMA's current CEO is John J. Castellani.
Campaign Finance$83,974,086 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Bundled ContributionsMoney raised by the firm from multiple donors on behalf of the recipient. The firm's own contributions are not included.
Recipient Lobbyist Amount National Republican Senatorial Cmte Jennifer A. Swenson $32,500
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Pharmaceutical Rsrch & Mfrs of America
Names of Lobbyists
Firm Hired Amount Pharmaceutical Rsrch & Mfrs of America $242,013,920 Brown & Assoc $20,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Consumer Product Safety,
- Science & Technology
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1548 Pathway for Biosimilars Act H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R.3200 America's Affordable Health Choices Act of 2009 S.515 Patent Reform Act of 2009 H.R.1260 Patent Reform Act of 2009 H.R.4872 Health Care and Education Affordability Reconciliation Act of 2010 H.R.3962 Affordable Health Care for America Act S.23 Patent Reform Act of 2011 S.726 Promoting Innovation and Access to Life-Saving Medicine Act
Recent Lobbying Contracts
Date Registrant Summary Sept. 13, 2013 Ferguson Strategies Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program; Public Law No. 111-148, the "Patiet Protection and Affordable Care Act" ; and Public Law No, 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act." View registration
RegulationsMentioned in 501 dockets; Submitted to 134 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Pharmaceutical Rsrch & Mfrs of America" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Pharmaceutical Rsrch & Mfrs of America
- Toggle 3 FDA Import for Export; Reporting & Recordkeeping Requirement 1998
- Toggle 3 USTR 2009 Special 301 2009
- Toggle 3 FDA Draft Guidance for Industry and Investigators on Safety Reporting Requirements for INDs and BA/BE Studies; Availability 2010
- Toggle 2 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Format Variations in the Brief Summary of Direct-to-Consumer (DTC) Print Advertisements. 2010
- Toggle 2 FDA Draft Guidance for Industry on Genotoxic and Carcinogenic Impurities in Drug Substances and Products 2008
- Toggle 2 FDA Electronic Records & Signatures, Retention of Electronic Rec 2000
- Toggle 2 FDA Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that are Regulated Under a Biologics License Application, and Animal Drugs 2005
- Toggle 2 FDA Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling 2006
- Toggle 2 FDA Draft Guidance for Industry on Control of Residual Solvents in Drug Products Marketed in the United States Availability 2008
- Toggle 2 FDA Section 112 - Fast Track Products - FDAMA 1998
Mentions in Document Text
View all mentions data for Pharmaceutical Rsrch & Mfrs of America
- Toggle 31 CMS Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests (CMS-5060-P) 2011
- Toggle 28 EPA Preliminary 2008 Effluent Guidelines Program Plan 2006
- Toggle 18 USTR 2010 Special 301 2010
- Toggle 18 EPA Greenhouse Gas Mandatory Reporting 2008
- Toggle 15 EPA Amendment to the Universal Waste Rule: Addition of Pharmaceuticals 2007
- Toggle 15 FDA Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing 2006
- Toggle 14 EPA Preliminary 2010 Effluent Guidelines Program Plan 2008
- Toggle 13 Comments received by the U.S. State Department on the Draft Supplemental Environmental Impact Statement for the Proposed Keystone XL Project 2013
- Toggle 13 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Healthcare Professional Survey of Prescription Drug Promotion 2012
- Toggle 13 FDA Section 301. Foreign Supplier Verification Program 2011
Advisory Committees2 people on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Pharmaceutical Rsrch & Mfrs of America" that sat on federal advisory committees.
- Toggle Department of Commerce 2 people on 1 committee